ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) plans to sell 33,150,000 shares at HK$7.05 apiece to investors under a placement deal, according to a Thursday filing with the Hong Kong Exchange.
The shares represent 8.14% of the pharmaceutical company's shareholding as enlarged by the placement.
Net proceeds of HK$229.7 million, will be used to fund studies for its non-small cell lung cancer, triple-negative breast cancer, and tumor treatments, and for working capital.
Shares slid 6% during Thursday's trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。